Workup for SLE and Antiphospholipid Syndrome
For suspected SLE, obtain ANA by immunofluorescence on HEp-2 cells at ≥1:80 titer as the mandatory entry test, followed by anti-dsDNA, complement levels (C3/C4), and complete blood count; for suspected APS, test for lupus anticoagulant, anticardiolipin antibodies (IgG/IgM), and anti-β2-glycoprotein I antibodies (IgG/IgM), with repeat testing at ≥12 weeks to confirm persistence.
SLE Diagnostic Workup
Initial Screening
- ANA testing is the essential entry criterion - ANA by immunofluorescence on HEp-2 cells at titer ≥1:80 has 97.8% sensitivity for SLE 1. Without a positive ANA (or equivalent solid-phase assay), SLE classification cannot proceed. This is non-negotiable.
Core Serological Panel (if ANA positive)
- Anti-dsDNA antibodies - correlates with disease activity and renal involvement 2
- Complement levels (C3 and C4) - low levels indicate active disease and predict flares 2
- Anti-Sm antibodies - highly specific for SLE 3
- Anti-Ro/SSA and anti-La/SSB antibodies - essential if pregnancy is considered (0.7-2% risk of congenital heart block) 4
- Anti-RNP antibodies - part of extractable nuclear antigen (ENA) panel 3
Additional Useful Tests
- Anti-C1q antibodies - useful for predicting renal flares, particularly in anti-dsDNA negative patients 3
- Anti-nucleosome antibodies - helpful for diagnosis and monitoring in dsDNA-negative patients 3
Hematologic Assessment
- Complete blood count - screen for cytopenias (leukopenia, lymphopenia, thrombocytopenia, hemolytic anemia) 2
Renal Evaluation
- Urinalysis with microscopy - assess for proteinuria and active sediment 2
- Serum creatinine and blood urea nitrogen - evaluate renal function 4
- 24-hour urine protein or spot urine protein-to-creatinine ratio 2
- Renal biopsy - indicated when lupus nephritis is suspected for classification and treatment planning 2
Antiphospholipid Syndrome Workup
Triple Test Approach (Mandatory)
The cornerstone of APS diagnosis requires testing for all three antibody types 5:
Lupus anticoagulant (LA) - most strongly associated with thrombosis and pregnancy morbidity 6, 7
- Use dilute Russell's viper venom time (dRVVT) and/or activated partial thromboplastin time (aPTT)-based assays
- Include mixing studies and confirmatory tests with phospholipid neutralization
Anticardiolipin antibodies (aCL) - IgG and IgM isotypes by ELISA 5
- Moderate titer: ≥40 Units
- High titer: ≥80 Units
- IgG isotype more strongly associated with thrombosis than IgM 7
Anti-β2-glycoprotein I antibodies (aβ2GPI) - IgG and IgM isotypes by ELISA 5
- Same titer thresholds as aCL (≥40 Units moderate, ≥80 Units high)
- IgG isotype shows stronger clinical associations 7
Critical Testing Requirements
- Repeat testing at ≥12 weeks - persistence of antibodies is mandatory for APS classification 5
- Test during stable clinical state - avoid testing during acute thrombosis or active infection when possible
- All three tests must be performed - LA performs better than isolated aCL or aβ2GPI testing 7
Risk Stratification by Antibody Profile
The antibody profile determines thrombotic risk 4:
High-risk profile:
- Lupus anticoagulant positive (strongest predictor)
- Multiple antibody positivity (LA + aβ2GPI + aCL)
- Moderate-to-high titers (≥40 Units)
- Triple positivity: LA + aβ2GPI + anti-PS/PT shows OR 23.2 for clinical events 6
Lower-risk profile:
- Single antibody positivity
- Low titers
- Isolated IgM positivity
Emerging Tests (Consider in Seronegative Cases)
- Anti-phosphatidylserine/prothrombin (aPS/PT) antibodies - IgG and IgM isotypes improve diagnostic accuracy, especially when combined with LA and aβ2GPI (OR 3.73 for APS) 6, 8, 9
- Particularly useful in SLE patients who are seronegative on conventional assays but have high clinical suspicion 8, 9
Combined SLE-APS Evaluation
When to Test for Both
Test for antiphospholipid antibodies in all SLE patients because 4, 2:
- Presence of aPL/APS is a major risk factor for adverse outcomes (Level 1A evidence)
- 30-40% of SLE patients have positive aPL
- Changes management regarding anticoagulation and pregnancy counseling
Integrated Testing Panel for SLE Patients
- ANA (entry criterion)
- Anti-dsDNA, complement (C3/C4)
- Complete aPL panel (LA, aCL IgG/IgM, aβ2GPI IgG/IgM)
- Anti-Ro/SSA and anti-La/SSB (if female of childbearing age)
- Complete blood count
- Renal function tests and urinalysis
Monitoring Parameters
For established SLE with or without APS 4, 2:
- Disease activity assessment - use validated indices
- Renal function - creatinine, urinalysis every visit
- Serological markers - C3/C4, anti-dsDNA for flare prediction
- Blood pressure monitoring - essential in both conditions 4
Common Pitfalls to Avoid
Do not diagnose SLE without positive ANA - ANA negativity has only 2.2% false-negative rate; reconsider diagnosis 1
Do not test aPL during acute thrombosis - transient positivity can occur; wait for stable state when possible
Do not rely on single positive aPL test - persistence at ≥12 weeks is mandatory 5
Do not use fixed cutoffs for non-ELISA aPL assays - ELISA remains the standard for aCL and aβ2GPI 5
Do not ignore IgA isotypes completely - while not in classification criteria, IgA aCL and aβ2GPI may be relevant in seronegative cases with high clinical suspicion 5
Do not forget to assess for lupus anticoagulant - LA is the strongest predictor of thrombosis, superior to aCL or aβ2GPI alone 6, 7
In SLE patients with negative conventional aPL but high clinical suspicion for APS, consider testing for aPS/PT antibodies 6, 8, 9